![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/07\/20260724_University_of_Hong_Kong_Technology_and_Modalities-768x421.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n University of Hong Kong (Academic)<\/p>\n Event Type<\/strong><\/p>\n Peer-Reviewed Publication (Mechanistic \/ Methodology)<\/p>\n Platform<\/strong><\/p>\n Single-Cell DNA Sequencing (Clonal Reconstruction)<\/p>\n Indication<\/strong><\/p>\n Acute Myeloid Leukemia<\/p>\n A peer-reviewed Leukemia paper published online July 23 integrates cohort genomics with single-cell DNA sequencing to argue that recurrent disruption of transcriptional, chromatin, RNA-splicing, and cohesin regulators generally precedes whole-chromosome gains in acute myeloid leukemia. Across 51,092 cells from 16 patients, all 14 informative trisomy-positive samples placed at least one regulatory mutation before or on the same branch as the gain, and 10 carried more than one such preceding mutation. The work provides a mechanistic model of cumulative genomic destabilization and a useful clonal-reconstruction method, but causality, generalizability, and therapeutic actionability remain unproven.<\/p>\n Investigators compared 1,650 cytogenetically normal AML cases with 229 trisomy-positive cases and identified significant enrichment of mutations including ASXL1, SRSF2, STAG2, and EZH2 after multiple-testing correction.<\/p>\n They then applied Mission Bio Tapestri single-cell DNA sequencing to 51,092 cells from 16 AML samples. Fourteen samples contained trisomy-positive cells suitable for temporal reconstruction.<\/p>\n In all 14 informative samples, at least one identified regulatory-gene mutation occurred before or on the same clonal branch as the chromosome gain. Ten of 14 samples, or 71%, carried more than one such mutation before or with trisomy.<\/p>\n The recurring order included lesions affecting ASXL1, SRSF2, RUNX1, cohesin, chromatin regulation, and RNA processing. Simulations favored a cumulative-mutation model over a null model of independent sudden chromosomal gain.<\/p>\n The study proposes that numerical chromosomal instability in AML can emerge after progressive damage to systems that maintain transcriptional control, chromatin state, RNA processing, and chromosome organization. This contrasts with a purely abrupt model in which trisomy appears as an isolated mitotic accident.<\/p>\n The result is consistent with age-related clonal evolution: early regulatory lesions may alter cellular state and genome maintenance, after which a whole-chromosome gain supplies additional dosage changes that support malignant expansion.<\/p>\n Bulk sequencing detects co-occurrence but cannot reliably order events when clones overlap. Single-cell DNA genotyping with ploidy-aware clonal reconstruction can place point mutations and chromosome gains within the same cellular phylogeny, providing a more direct temporal model.<\/p>\n The combination of large-cohort enrichment and targeted single-cell validation is stronger than either alone. The approach can be extended to other aneuploid myeloid neoplasms and to longitudinal samples collected from clonal hematopoiesis through MDS and AML.<\/p>\n If validated prospectively, combinations of regulatory mutations may help identify clones at elevated risk of acquiring aneuploidy and progressing. This could refine surveillance beyond single-driver mutation status, particularly in clonal hematopoiesis or early myeloid disease.<\/p>\n The study does not establish a drug target. Potential dependencies created by aneuploidy, spliceosome dysfunction, cohesin loss, or chromatin disruption require functional perturbation studies before therapeutic claims are justified.<\/p>\n The single-cell cohort is small and selected, and targeted panels cannot capture every mutation or structural event. Temporal ordering is inferred from sampled phylogenies rather than observed continuously, and mutations assigned to the same branch may not be precisely ordered.<\/p>\n The very large modeled likelihood ratio depends on assumptions in the simulation and should not be read as a direct measure of biological effect size. Functional causality must be tested in engineered HSC or AML systems and ideally in longitudinal patient samples.<\/p>\n Acute myeloid leukemia is a clonal malignancy of myeloid progenitors characterized by impaired differentiation, abnormal proliferation, and genomic evolution. Whole-chromosome gains occur in subsets of AML and can alter the dosage of hundreds of genes, but their temporal origin has been difficult to resolve.<\/p>\n The study was led by academic investigators using cohort genomics, Mission Bio Tapestri single-cell DNA sequencing, clonal phylogenetics, and simulation. It is a peer-reviewed Letter in Leukemia rather than a company-sponsored therapeutic readout.<\/p>\n This paper merits coverage because it changes the model of how a recurrent cytogenetic class can arise in AML and demonstrates a tractable single-cell framework for reconstructing that process.<\/p>\n Its value is mechanistic and methodological, not yet therapeutic. The next decisive evidence would engineer defined regulatory-lesion combinations in HSC models and test whether they reproducibly increase chromosome-gain frequency or create selective dependencies.<\/p>\n Signal strength:<\/strong> 3\/5 \u2014 Medium-High. Importance:<\/strong> Medium-High \u2014 the study introduces a mechanistic framework for AML aneuploid evolution and validates a useful single-cell analytic approach in a core hematology domain. Confidence:<\/strong> High for the reported cohort associations and inferred clonal ordering; medium for causality, clinical risk prediction, and therapeutic relevance because the single-cell sample is limited and functional validation is absent.<\/p>\n","protected":false},"excerpt":{"rendered":" A peer-reviewed Leukemia paper published online July 23 integrates cohort genomics with single-cell DNA sequencing to argue that recurrent disruption of transcriptional, chromatin, RNA-splicing, and cohesin regulators generally precedes whole-chromosome gains in acute myeloid…<\/p>\n","protected":false},"author":1,"featured_media":2171,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,4],"tags":[76,184],"class_list":["post-2153","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-technology-modalities","tag-acute-myeloid-leukemia","tag-university-of-hong-kong"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2153"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2153\/revisions"}],"predecessor-version":[{"id":2182,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2153\/revisions\/2182"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2171"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Biological Interpretation<\/h4>\n
Methodological Significance<\/h4>\n
Translational Implications<\/h4>\n
Limitations<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n